CLEVELAND, May 2 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BostonStockExchange:CFB), today announced that has published an update on the Company. The video podcast can be accessed at

In addition to highlighting recent developments at the Company, the interview featured commentary from Stephen Brozak of WBB Securities, LLC that recently initiated coverage of Cleveland BioLabs with a Buy rating.

In discussing the significance of Cleveland BioLabs's radiation protection platform, Brozak observed that the Company's commercial opportunities fall into two primary categories. The first is the HHS (Department of Health and Human Services) and BARDA (Biomedical Advanced Research and Development Authority) category, which deals with unintended radiation exposure. He stated that the Company has a unique opportunity to address radiation exposure, since there are not currently any existing products available that offer meaningful solutions. In addition, Brozak highlighted the Company's potential for traditional medical indications for the same technology.

Brozak commented on the Company's submission of a proposal to the Department of Defense (DoD) for its lead radiation protection compound Protectan CBLB502, stating, "For the first time, Cleveland BioLabs offers a promising solution and the very realistic possibility of gaining a contract. If they get a contract, it may mean repeat contracts, as well as other potential uses down the road. This is one of the areas we focused on when we looked at the Company."

"What's really attractive, is the understanding of the HHS government contracting system," added Brozak. "Cleveland BioLabs is distinguishing themselves in their potential to procure revenues through government contracting."

Brozak also noted that the Company's recent stem cell discoveries around its Protectan CBLB612 compound may have significant potential for the stem cell transplantation market, if results continue to be borne out in future stages of development.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release does not suggest or imply an endorsement by the Company of any projection or recommendation provided by any analyst or analyst report.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our filings with the Securities and Exchange Commission.

    The Global Consulting Group
    Rachel Levine
    T: (646) 284-9439